NASD · Healthcare · Biotechnology · USA
Greenwich LifeSciences Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing GLSI-100, an immunotherapy pairing a HER2/neu peptide with an immune-stimulating agent to reduce breast cancer recurrence. The company is conducting the Flamingo-01 Phase III trial in patients with HER2/neu-positive tumors who have undergone standard treatment and remain at risk of disease return.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Greenwich LifeSciences Inc stock.
Not valued: We cannot value this company yet.
14 more funds hold it; the full list is part of the paid plan.
129 more in this industry show a wider margin of safety.
We do not publish a verdict on GLSI yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.